Quantcast
  • E-mail
  • Print
  • Comment
  • Font Size
  • Digg
  • del.icio.us
  • Discuss article

Cepheid Wins FDA Clearance to Market Molecular Diagnostic Test

Posted on: Tuesday, 30 September 2008, 09:01 CDT

Cepheid, a molecular diagnostics company, has received clearance from the FDA to market its Xpert MRSA/SA skin and soft tissue infection test, which runs on the GeneXpert system, for the rapid detection of Methicillin-resistant Staphylococcus aureus and Methicillin-sensitive Staphylococcus aureus in skin and soft tissue infections.

In less than one hour, Xpert MRSA/SA skin and soft tissue infections test processes specimens from suspected skin and soft tissue infection swabs to determine if a patient is infected with Methicillin-resistant Staphylococcus aureus (MRSA) or SA, giving physicians and surgeons a powerful new tool to aid in selecting the most effective antibiotic therapy to improve patient management, the company said.

John Bishop, Cepheid's CEO, said: "The ability to accurately identify MRSA and SA on a more timely basis is important in managing both hospital-acquired and community-acquired infections. With our expanding test menu, we expect Cepheid's GeneXpert system to continue to be the molecular platform of choice for the management of healthcare acquired infections."


Source: Datamonitor

More News in this Category


Related Articles



Rating: 2.9 / 5 (7 votes)
Rate this article:
1/52/53/54/55/5

User Comments (0)

Comment on this article

Your Name
Text from the image
Comment
max 1200 chars
* All fields are required